Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegtibatinase in Classical Homocystinuria (ENSEMBLE)
NCT06431893Phase 3Enrolling by invitation
- Sponsor
- Travere Therapeutics
- Start
- Apr 2024
- Primary completion
- Aug 2030
- Modality
- Replacement Enzymes
- Countries
- 14
01
Overview
Phase 3, open-label, single-arm trial of pegtibatinase in homocystinuria (HCU), sponsored by Travere Therapeutics. Primary endpoints: Treatment-emergent Adverse Events, Incidence of Hypermethioninemia and 2 more. Started Apr 2024; status: enrolling by invitation.
02
Drugs
pegtibatinase
03
Conditions
homocystinuria (HCU)
Beyond the preview
Go deeper on NCT06431893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06431893.